Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigehiro Katayama

Showing results (1-10 of 126) with videos related to

Pageof 13
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 25, 2003
[Guidelines for the treatment of hypertension in diabetics]Shigehiro Katayama
Nihon Rinsho. Japanese Journal of Clinical Medicine|May 8, 2010
[Treatment of hypertension to prevent cardiovascular disease in diabetics]Shigehiro Katayama
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 25, 2011
[Treatment of hypertension in patients associated with type 2 diabetes mellitus or metabolic syndrome]Shigehiro Katayama
Clinical Calcium|October 4, 2005
[Clinical significance of calcium channel blocker in patients with metabolic syndrome]Shigehiro Katayama
Clinical Calcium|April 2, 2005
[Osteoporosis and intake of carbohydrates]Konosuke Nakayama, Shigehiro Katayama
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 23, 2004
[Total care for patients with metabolic syndrome]Nobuki Takata, Shigehiro Katayama
Current Drug Targets. Cardiovascular & Haematological Disorders|March 23, 2004
The possible therapeutic actions of peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists, PPAR gamma agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, angiotensin converting enzyme (ACE) inhibitors and calcium (Ca)-antagonists on vascular endothelial cellsIkuo Inoue, Shigehiro Katayama
Heart and Vessels|August 16, 2002
Carbon monoxide regulates blood pressure cooperatively with nitric oxide in hypertensive ratsMasayuki Ushiyama, Toshisuke Morita, Shigehiro Katayama
Recent Patents on Cardiovascular Drug Discovery|April 29, 2010
Retrospective, observation study: Quantitative and qualitative effect of ezetimibe and HMG-CoA reductase inhibitors on LDL-cholesterol: are there disappearance thresholds for small, dense LDL and IDL?Ikuo Inoue, Takuya Awata, Shigehiro Katayama
Hypertension Research : Official Journal of the Japanese Society of Hypertension|February 7, 2018
Clinical features and therapeutic perspectives on hypertension in diabeticsShigehiro Katayama, Masako Hatano, Masashi Issiki
Pageof 13

Showing results (1-10 of 126) with videos related to

Sort By:
Pageof 13
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 25, 2003
[Guidelines for the treatment of hypertension in diabetics]Shigehiro Katayama
Nihon Rinsho. Japanese Journal of Clinical Medicine|May 8, 2010
[Treatment of hypertension to prevent cardiovascular disease in diabetics]Shigehiro Katayama
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 25, 2011
[Treatment of hypertension in patients associated with type 2 diabetes mellitus or metabolic syndrome]Shigehiro Katayama
Clinical Calcium|October 4, 2005
[Clinical significance of calcium channel blocker in patients with metabolic syndrome]Shigehiro Katayama
Clinical Calcium|April 2, 2005
[Osteoporosis and intake of carbohydrates]Konosuke Nakayama, Shigehiro Katayama
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 23, 2004
[Total care for patients with metabolic syndrome]Nobuki Takata, Shigehiro Katayama
Current Drug Targets. Cardiovascular & Haematological Disorders|March 23, 2004
The possible therapeutic actions of peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists, PPAR gamma agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, angiotensin converting enzyme (ACE) inhibitors and calcium (Ca)-antagonists on vascular endothelial cellsIkuo Inoue, Shigehiro Katayama
Heart and Vessels|August 16, 2002
Carbon monoxide regulates blood pressure cooperatively with nitric oxide in hypertensive ratsMasayuki Ushiyama, Toshisuke Morita, Shigehiro Katayama
Recent Patents on Cardiovascular Drug Discovery|April 29, 2010
Retrospective, observation study: Quantitative and qualitative effect of ezetimibe and HMG-CoA reductase inhibitors on LDL-cholesterol: are there disappearance thresholds for small, dense LDL and IDL?Ikuo Inoue, Takuya Awata, Shigehiro Katayama
Hypertension Research : Official Journal of the Japanese Society of Hypertension|February 7, 2018
Clinical features and therapeutic perspectives on hypertension in diabeticsShigehiro Katayama, Masako Hatano, Masashi Issiki
Pageof 13